Employers Reassess Health Benefits as GLP-1 Drug Costs Strain Budgets
Employers are fundamentally reconsidering health benefit design as spending on GLP-1 medications (Ozempic, Wegovy, Mounjaro) drives unprecedented cost increases. Self-insured employers and commercial health plans are implementing new coverage restrictions, prior authorization requirements, and cost-sharing structures to manage expenses that some benefit managers describe as unsustainable under current benefit designs. The shift is occurring across 2026 plan years as employers finalize benefits for 2027. This development matters primarily for commercial payers but has spillover implications for Medicaid programs in states that cover GLP-1s for weight loss, as commercial market strategies often preview Medicaid managed care utilization management approaches.
Commercial employer strategies for managing GLP-1 utilization and costs typically influence Medicaid managed care plan approaches to coverage, formulary placement, and prior authorization requirements.
Pharmacy · Managed Care
You might also like